Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bifidobacterium and rTMS in Adolescent Depression
NCT06325605Completed
- Start
- Mar 2022
- Primary completion
- Oct 2022
- Modality
- Live Biotherapeutic Products
- Countries
- 1
01
Overview
Randomised, double-blind trial of Bifidobacterium tetravaccine in major depressive disorder (MDD). Primary endpoint: Hamilton Rating Scale for Depression at 8 weeks. Started Mar 2022; status: completed.
02
Drugs
Bifidobacterium tetravaccine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT06325605.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06325605.